Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
99316 trials found · Page 4 of 4966
-
New antibody boosts hope for cure in blood disorders
⭐️ CURE ⭐️ OngoingBackground: Sickle cell disease (SCD) is an inherited disorder of the blood. It can damage a person s organs and cause serious illness and death. A blood stem cell transplant is the only potential cure for SCD. Treatments that improve survival rates are needed. Objective: To f…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: ⭐️ CURE ⭐️
Last updated May 18, 2026 12:02 UTC
-
CRISPR gene therapy may free kids with thalassemia from lifelong transfusions
Disease control OngoingThis is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
CRISPR therapy aims to stop pain crises in kids with sickle cell
Disease control OngoingThis is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated May 30, 2026 11:36 UTC
-
Major RSV vaccine trial aims to shield seniors from severe lung infections
⭐️ VACCINE ⭐️ OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 22, 2026 14:03 UTC
-
Twice-a-year shot could revolutionize HIV prevention for young women
Prevention OngoingThe goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW). The primary objective of this study is to evaluate the efficacy of LE…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated May 29, 2026 14:19 UTC
-
Gene therapy hope for babies with fatal brain disease
Disease control OngoingJ3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
Twice-Yearly shot shows promise in preventing HIV
Prevention OngoingThe goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection. The primary ob…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated May 29, 2026 14:17 UTC
-
Brain gene therapy offers hope for rare childhood disease
Disease control ENROLLING_BY_INVITATIONCanavan Disease is a congenital white matter disorder caused by mutations to the gene encoding for aspartoacylase (ASPA). Expression of ASPA is restricted to oligodendrocytes, the sole white matter producing lineage in the brain. ASPA supports myelination in the capacity of its s…
Phase: PHASE1, PHASE2 • Sponsor: Myrtelle Inc. • Aim: Disease control
Last updated May 29, 2026 14:18 UTC
-
Stem cell therapy could free type 1 diabetes patients from insulin injections
Disease control Recruiting nowThis study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
Engineered immune cells offer new hope for kids with Tough-to-Treat leukemia
Disease control OngoingThis study aims at evaluating the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B-cell surface antigen CD19, following administration of lymphodepleting chemotherapy…
Phase: PHASE1, PHASE2 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
Could a single gene therapy help boys with duchenne walk stronger?
Disease control OngoingThe study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
Could a stem cell transplant cure immune diseases?
⭐️ CURE ⭐️ Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated May 27, 2026 11:49 UTC
-
One-Time gene therapy aims to stop bleeding in severe hemophilia
Disease control OngoingC3731003 is a pivotal Phase 3 study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants with moderately severe or severe hemophilia A (FVII…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 27, 2026 11:50 UTC
-
Global brain cancer trial aims to outsmart glioblastoma
Disease control Recruiting nowGlioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enro…
Phase: PHASE2, PHASE3 • Sponsor: Global Coalition for Adaptive Research • Aim: Disease control
Last updated May 27, 2026 23:06 UTC
-
One-Time gene therapy could slash bleeding in hemophilia b
Disease control OngoingThis study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less). The gene therapy is designed to introduce geneti…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Groundbreaking study offers face and hand transplants to 10 patients
Disease control Recruiting nowThe purpose of this study is to evaluate functional and aesthetic outcomes of combined facial and upper extremity composite tissue allografts on patients who have not achieved functional and aesthetic outcomes with conventional reconstructive surgical strategies and prosthetic de…
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
One-Time gene therapy helps babies with rare muscle disease sit on their own
Disease control CompletedThis is a Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in participants with spinal muscular atrophy (SMA) Type 1 and who are genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 ge…
Phase: PHASE3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated May 29, 2026 14:16 UTC
-
Promising Alzheimer's drug moves to final testing phase
Disease control OngoingThis study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months…
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated May 29, 2026 14:19 UTC
-
Massive malaria vaccine trial shows promise for protecting young children
⭐️ VACCINE ⭐️ CompletedThe RTS, S/AS01E vaccine was developed to protect children in sub-Saharan Africa from malaria as part of routine immunization programs. This study aims to check the vaccine's safety after it has been introduced. Along with safety, researchers will also assess how well the vaccine…
Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated May 29, 2026 14:16 UTC
-
CRISPR gene therapy frees patients from lifelong blood transfusions
Disease control CompletedThis is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPC…
Phase: PHASE2, PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated May 30, 2026 11:36 UTC